Annual Meeting Highlights
|ASH 2016 Annual Meeting Highlights in Myelodysplastic Syndromes|
CME, CPE, CNE
Guillermo Garcia-Manero, MD; Guillermo Montalbán Bravo, MD; Mikkael A. Sekeres, MD, MS; and David P. Steensma, MD, FACP
|Release Date: January 11, 2017|
Expiration Date: January 11, 2018
|Health care providers, especially community-based practitioners, are challenged with attending major medical conferences, learning about new data, and understanding their relevance and potential impact on clinical practice. In this activity, participants will learn about key highlights of the most impactful and groundbreaking data in myelodysplastic syndromes (MDS), presented at the 2016 American Society of Hematology (ASH) annual meeting. Leading experts in the field of MDS will share their insights on a variety of abstracts, covering topics including, but not limited to, hypomethylating agents, immunomodulatory drugs, and new combination therapies.
Provided by MediCom Worldwide, Inc.
This activity is supported by an educational grant from Celgene Corporation
|Begin, Earn CreditView Only, No Credit|